eCoin Tibial Nerve Stimulation for OAB

Subcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence

The study is a single arm, prospective study of the safety and effectiveness of the Valencia Technologies eCoin System to stimulate the tibial nerve for the treatment of patients with refractory urgency urinary incontinence.

Study Overview

• Status: Completed
• Conditions: Urgency Urinary Incontinence
• Intervention / Treatment: Device: eCoin

Detailed Description

This trial is a single arm, prospective study of the safety and effectiveness of eCoin tibial nerve stimulation in 25 subjects with refractory overactive bladder as defined by the American Urological Association.. The eCoin neuromodulation device will be implanted subcutaneously in the right or left leg of patients with urgency urinary incontinence. After a 4 week implant healing period, subjects will have their devices activated (turned ON). After 3 months of device therapy (occurring 4 months post-implant), the primary endpoint will be assessed. It is anticipated that subjects will reach the full therapeutic effect at approximately 3 months of therapy. Subjects will be followed for an additional 9 months to assess the safety of maintenance stimulation therapy with fewer sessions occurring during this time interval.

• Study Type: Interventional
• Enrollment (Actual): 46
• Phase: Not Applicable

Contacts and Locations

Study Locations

• New Zealand
  • Christchurch, New Zealand, 8013
    • Urology Associates
  • Nelson, New Zealand
    • Roundhay Medical Centre
  • Tauranga, New Zealand
    • Tauranga Urology Research Ltd
• United States
  • California
    • Newport Beach, California, United States, 92663
      • The Clark Center for Urogynecology
  • Iowa
    • Waterloo, Iowa, United States, 50703
      • UnityPoint Clinic
  • North Carolina
    • Greensboro, North Carolina, United States, 27403
      • Alliance Urology Specialists
  • Pennsylvania
    • Allentown, Pennsylvania, United States, 18103
      • The Institute for Female Pelvic Medicine & Reconstructive Surgery (FPM Institute)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Women and men 18 years and older.
2. Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component, for at least 6 months (self-reported).
3. Individual has at least four urgency incontinence episodes on a three-day voiding diary with at least one episode per 24 hour time period
4. Individual with urinary frequency, defined as an average of greater than or equal to 8 times/24 hours (ie. a total of greater than or equal to 24 micturitions on a 3 day diary)
5. Individual is unresponsive to, inadequately responsive to, or intolerant of behavioral, rehabilitation, and pharmacologic therapy.
6. Individual is able to give his or her written, informed consent.
7. Individual is mentally competent and able to understand all study requirements.
8. Individual is willing and able to complete a 3-day voiding diary and quality of life questionnaire.
9. Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists) for 2 weeks prior to screening.
10. The individual demonstrates a positive nerve integrity test.

Exclusion Criteria:

1. Individual has predominantly stress urinary incontinence
2. Individual has clinically significant bladder outlet obstruction.
3. Individual has clinically significant pelvic organ prolapse.
4. Individual has abnormal post void residual (i.e., greater than 150 cc).
5. Individual has clinically significant urethral stricture disease or bladder neck contracture
6. Individual has an active urinary tract infection at time of enrollment.
7. Individual has recurrent urinary tract infections defined as 4 or more UTI's per year.
8. Individual has morbid obesity.
9. Individual has had positive urine cytology or diagnosis of bladder or prostate cancer.
10. Individual has neurogenic bladder dysfunction.
11. Individual is taking an alpha-blocker for benign prostatic hyperplasia.
12. Individual is pregnant or intends to become pregnant during the study.
13. Patient is breast feeding or is less than 9-month post-partum.
14. Individual has the presence of urinary fistula, bladder stone, or interstitial cystitis.
15. Individual has uncontrolled diabetes mellitus.
16. Individual has a cardiac pacemaker or implanted defibrillator.
17. Individual has been previously treated with sacral nerve stimulation.
18. Individual has been treated with onabotulinumtoxinA in the previous 9 months prior to enrollment.
19. Individual has been treated with percutaneous tibial nerve stimulation within the previous 12 weeks prior to enrollment.
20. Individual requires regular Magnetic Resonance Imaging for other health care conditions. (ASK)
21. Individual has a clotting or bleeding disorder; antiplatelet and anticoagulant therapy may be continued or held at the discretion of the investigator
22. Individual has a clinically significant peripheral neuropathy.
23. Individual is neutropenic or immunocompromised.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Treatment Arm; Treatment Arm receives implanted eCoin device and therapy is turned ON.	Device: eCoin; Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incontinent Episodes	The change in number of incontinence episodes from baseline to three months post-activation.	Baseline to three months post-activation.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
System and Procedure Related AEs	Number of System and Procedure Related Adverse Events from implantation to one month post-implantation.	Implantation to one month post-implantation.
MAEs	Number of all Major Adverse Events from baseline to 3 months post-activation.	Baseline to 3 months post-activation.
Percentage of Responders	Percentage of Responders, defined as participants who experienced a 50% or greater reduction in UUI after 3 months of treatment	3 months after activation

Collaborators and Investigators

• Sponsor: Valencia Technologies Corporation
• Investigators: Principal Investigator: Sharon English, MD, Urology Associates; Principal Investigator: Scott MacDiarmid, MD, Alliance Urology Specialists

Publications and helpful links

General Publications

• Kaaki B, English S, Gilling P, Meffan P, Lucente V, MacDiarmid S, Clark M, Sen SK. Six-Month Outcomes of Reimplantation of a Coin-Sized Tibial Nerve Stimulator for the Treatment of Overactive Bladder Syndrome With Urgency Urinary Incontinence. Female Pelvic Med Reconstr Surg. 2022 May 1;28(5):287-292. doi: 10.1097/SPV.0000000000001105. Epub 2022 Sep 22.

Study record dates

Study Major Dates

• Study Start (Actual): April 3, 2017
• Primary Completion (Actual): December 30, 2017
• Study Completion (Actual): October 1, 2018

Study Registration Dates

• First Submitted: January 20, 2017
• First Submitted That Met QC Criteria: January 20, 2017
• First Posted (Estimate): January 24, 2017

Study Record Updates

• Last Update Posted (Actual): December 22, 2020
• Last Update Submitted That Met QC Criteria: November 30, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Urologic Diseases; Lower Urinary Tract Symptoms; Urological Manifestations; Urination Disorders; Elimination Disorders; Urinary Incontinence; Enuresis
• Other Study ID Numbers: 111-3175

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes